期刊文献+

他汀类药物治疗慢性阻塞性肺疾病合并肺动脉高压的Meta分析 被引量:12

Effects of statins on patients with chronic obstructive pulmonary disease complicated with pulmonary hypertension:A Meta-analysis
下载PDF
导出
摘要 目的系统评价他汀类药物(statins)治疗慢性阻塞性肺疾病(COPD)合并肺动脉高压(PH)的临床疗效。方法系统检索PubMed、CBM、维普、万方等数据库,全面收集他汀类药物治疗慢性阻塞性肺疾病合并肺动脉高压的随机对照试验(RCT)。按纳入排除标准筛选文献、提取资料和进行方法学质量评价,并采用RevMan 5.0软件进行Meta分析。结果共纳入7个RCT,共计467例患者。包括2个安慰剂对照试验和5个非安慰剂对照试验。Meta分析结果显示:①statin能改善患者平均肺动脉压(mPAP)值[MD=-3.83mmHg,95%CI(-5.22,-2.43)],肺动脉收缩压(PASP)值[MD=-5.66mmHg,95%CI(-7.15,-4.16)],与对照组比较,差异有统计学意义。②statin能显著降低患者内皮素-1(ET-1)值[MD=-3.51pg/ml,95%CI(-4.77,-2.55)]、增高一氧化氮(NO)值[SMD=1.06,95%CI(0.81,1.31)],与对照组相比,差异有统计学意义。③statin能改善患者第一秒用力呼气量占预计值的百分比(FEV1%)[MD=9.79,95%CI(6.05,13.52)]。结论他汀类药物应用于COPD合并PH患者能显著改善患者的肺动脉压,改善肺功能,提高临床疗效。 Objective To evaluate the effects of statin treatment combined with conventional therapy in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension(PH) . Methods Literatures published were searched completely in the databases including PubMed,CBM, VIP and WANGFANG to collect the randomized control trials(RCTs ) of statin combined with the conventional treatment versus the conventional treatment on patients with stable COPD. The studies were evaluated and screened strictly according to the inclusive and exclusive criteria. And meta --analysis was conducted by RevMan 5.0 software. Results Seven RCTs were included and 467 patients with stable COPD and PH met inclusion criterion. The recta--analysis showed that,compared with control group, a)the statin therapy could lower mean pulmonary artery pressure(mPAP) [MD= -3.83 mmHg,95%CI(-5. 22,-2. 43)] as well as pulmonary arterial systolic pressure(PASP) [MD= - 5.66 mmHg, 95 % CI( -- 7.15, - 4. 16) ] significantly in patients ; b) the statin treatment could excessively reduce endothelin-1 (ET-1 ) [ MD = -- 3.51 pg/ml, 95% CI ( - 4.77, - 2.55 )], and improve the value of nitric oxide(NO) in blood [SMD= 1.06umol/1,95 %CI(O. 81,1.31) ] ; and c) the statin therapy could improve FEV1 %[SMD=9.79,95%CI(6.05,13.52)]. Conclusion The use of statins in the stable COPD patients combined with PH can excessively lower the pulmonary hypertension, improve pulmonary function as well as clinical effectiveness.
作者 李敏 文富强
出处 《西部医学》 2013年第1期20-24,共5页 Medical Journal of West China
基金 国家科技支撑计划资助项目(2012BAI05B02)
关键词 慢性阻塞性肺疾病 他汀类药物 META分析 系统评价 随机对照试验 Chronic obstructive pulmonary disease Pulmonary hypertension Statins Meta-- analysis Systematic review Randomized controlled trials
  • 相关文献

参考文献11

二级参考文献46

  • 1殷宗宝,邓超,陈栩栩,周有泠,曹玉芳.辛伐他汀对慢性低氧高二氧化碳所致大鼠肺动脉高压的干预作用[J].中华临床医师杂志(电子版),2011,5(7):1993-1997. 被引量:2
  • 2陆慰萱.肺动脉高压的新分类[J].中国实用内科杂志,2006,26(1):60-62. 被引量:12
  • 3安维洲,董砚虎.他汀类药物的非调脂作用研究现状[J].国际内分泌代谢杂志,2006,26(2):90-92. 被引量:7
  • 4Miettinen TA, Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of stalin treatment. Eur J Clin Invest, 2003, 33:976-982.
  • 5Ndrepepa G, Braun S, Von Beckerath N, et al. Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clin Chim Acta , 2005, 360 : 178- 186.
  • 6Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation , 2004, 109 : II42-48.
  • 7Ito MK, pleiotropy: reduction. 98S-101S; Talbert RL, Tsimikas S: Statin-associated possible beneficial effects beyond cholesterol Pharmacotherapy, 2006, 26 : 85S-97S; discussion quiz 106S-108S.
  • 8Liao JK. Clinical implications for statin pleiotropy. Curt Opin Lipidol ,2005, 16:624-629.
  • 9Rubin LJ. Therapy of pulmonary hypertension : the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med, 2002, 166:1308-1309.
  • 10Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med, 2002, 166:1403-1408.

共引文献86

同被引文献129

  • 1葛晓燕.他汀类药物治疗COPD合并PH患者疗效及安全性的荟萃分析[J].医学信息(医学与计算机应用),2014,0(13):124-125. 被引量:3
  • 2王秋芬,廖玉华.欧洲心脏病协会2004年肺动脉高压诊断和治疗指南简介[J].临床心血管病杂志,2005,21(7):385-386. 被引量:57
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 4陈灏珠,主编.实用内科学[M]第12版.北京:人民卫生出版社,2005.1 231-1 245.
  • 5蔡柏蔷.呼吸内科学[M].北京:中国协和医科大学出版社,2000.812.
  • 6SIMONNEAU G, GATZOULIS M A, ADATIA I, et al. Updated clinical classification of pulmonary hypertension [J]. J Am Coll Cardiol, 2013, 62(25 Suppl): D34-D41.
  • 7HSU H H, RUAN T, KO W J, et al. Effects of simvastatin on pulmonary C-fiber sensitivity in rats with monocrotaline- induced pulmonary hypertension [J]. J Heart Lung Transplant, 2011, 30(3): 332-340.
  • 8GAO Y F, ZHU X D, SHI D M, et al. The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats[J]. Int J Mol Med, 2010, 26(4): 541-547.
  • 9DEMARCO V G, HABIBI J, WHALEY-CONNELL A T, et al. Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2) 27 rat[J]. Am J Physiol Heart Circ Physiol, 2009, 297(3) : H1128-H1139.
  • 10LEE T M, CHEN C C, SHEN H N, et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension [J]. Clin Sci (Lond), 2009, 116(6): 497-505.

引证文献12

二级引证文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部